Compare GPRE & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPRE | IRWD |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.2M | 663.6M |
| IPO Year | 2004 | 2009 |
| Metric | GPRE | IRWD |
|---|---|---|
| Price | $15.60 | $4.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $12.57 | $7.67 |
| AVG Volume (30 Days) | 1.4M | ★ 2.3M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | ★ 0.42 | 0.24 |
| Revenue | ★ $2,091,680,000.00 | $298,276,000.00 |
| Revenue This Year | N/A | $57.95 |
| Revenue Next Year | $11.85 | $4.39 |
| P/E Ratio | $37.76 | ★ $17.17 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $7.08 | $0.67 |
| 52 Week High | $18.94 | $5.78 |
| Indicator | GPRE | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 53.16 | 64.61 |
| Support Level | $14.31 | $3.08 |
| Resistance Level | $15.64 | $4.50 |
| Average True Range (ATR) | 0.70 | 0.22 |
| MACD | 0.16 | 0.08 |
| Stochastic Oscillator | 67.50 | 91.67 |
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.